Citations

Clear

3042 citation(s) found for "Kumar, S".

Long‐term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience
Kourelis, Taxiarchis , Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Go, Ronald S. , Kapoor, Prashant , Lust, John A., Hayman, Suzanne R. , Hwa, Yi L. , Zeldenrust, Steven R., Russell, Stephen J. , Lin, Yi , Kyle, Robert A. , Dispenzieri, Angela , Kourelis, Taxiarchis V, Buadi, Francis K. , Go, Ronald S , Hwa, Yi, Gertz, Morie A. , Rajkumar, S. Vincent , Leung, Nelson , Gonsalves, Wilson I. , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | March 14, 2016 | Volume: 91 | Issue: 6 | Pages: 585-589

10.1002/ajh.24356 | PMID 26972803 Get It

Over the past decade, a number of changes have occurred in the diagnostic evaluation, management, and long‐term follow‐up of patients with POEMS syndrome at our institution. This study included 291 patients with POEMS syndrome diagnosed at the Mayo Clinic between 1974 and 2014. Patients diagnosed after 2003 had more features of the syndrome identified at diagnosis and were more likely to receive an autologous transplant (49% versus 8%, P < 0.0001) and to have achieved a hematologic complete response (CR) to treatment (41% vs 25%, P < 0.0001). With 2273 person‐years of follow‐up, 10‐year overall survival (OS) was 62% (95% C.I., 56%, 67%). On multivariate analysis, the three factors associated with superior OS were younger age (RR 0.98 [0.96–1.00]), albumin greater‐than 3.2 g/dL (RR 0.5 [0.32–0.89]) and attainment of complete hematologic response (RR 0.4 [0.2, 0.9]). This study confirms the very good long‐term outcomes of patients with POEMS syndrome and identifies two new prognostic risk factors: albumin at diagnosis and attainment of complete hematologic response. Am. J. Hematol. 91:585–589, 2016. © 2016 Wiley Periodicals, Inc.
Hyperinsulinemia adversely affects lung structure and function
Singh, Suchita, Bhatraju, Naveen Kumar , Pattnaik, Bijay , Gheware, Atish , Parameswaran, Praveen Kolumam, Freeman, Michelle, Mabalirajan, Ulaganathan , Gosens, Reinoud , Ghosh, Balaram , Linneberg, Allan , Prakash, Y. S. , Agrawal, Anurag , Pabelick, Christina, Bodas, Manish , Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S , Gosens, Reinoud , Bhatraju, Naveen Kumar

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | February 26, 2016 | Volume: 310 | Issue: 9 | Pages: L837-L845

10.1152/ajplung.00091.2015 | PMID 26919895 Get It

There is limited knowledge regarding the consequences of hyperinsulinemia on the lung. Given the increasing prevalence of obesity, insulin resistance, and epidemiological associations with asthma, this is a critical lacuna, more so with inhaled insulin on the horizon. Here, we demonstrate that insulin can adversely affect respiratory health. Insulin treatment (1 μg/ml) significantly ( P < 0.05) increased the proliferation of primary human airway smooth muscle (ASM) cells and induced collagen release. Additionally, ASM cells showed a significant increase in calcium response and mitochondrial respiration upon insulin exposure. Mice administered intranasal insulin showed increased collagen deposition in the lungs as well as a significant increase in airway hyperresponsiveness. PI3K/Akt mediated activation of β-catenin, a positive regulator of epithelial-mesenchymal transition and fibrosis, was observed in the lungs of insulin-treated mice and lung cells. Our data suggests that hyperinsulinemia may have adverse effects on airway structure and function. Insulin-induced activation of β-catenin in lung tissue and the contractile effects on ASM cells may be causally related to the development of asthma-like phenotype.
Clinical characteristics and outcomes in biclonal gammopathies
Mullikin, Trey C. , Dispenzieri, Angela , Lacy, Martha Q. , Lin, Yi , Dingli, David , Go, Ronald S. , Hayman, Suzanne R. , Zeldenrust, Steven R., Russell, Stephen J. , Lust, John A., Kapoor, Prashant , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Rajkumar, S. Vincent , Leung, Nelson , Gertz, Morie A. , Go, Ronald S , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | February 3, 2016 | Volume: 91 | Issue: 5 | Pages: 473-475

10.1002/ajh.24319 | PMID 26840395 Get It

A single monoclonal protein typically characterizes monoclonal gammopathies, but a small proportion may have more than one M protein identifiable. In the setting of symptomatic multiple myeloma (MM), the development of a new monoclonal protein following therapy is associated with better outcomes. As for the precursor conditions, monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM), there is limited information on the impact of a second monoclonal protein on the disease course, including progression and response to treatment. The outcomes of patients with MGUS and SMM with more than one monoclonal protein, after identifying 539 patients with biclonal proteins on electrophoresis and/or immunofixation, were reported. About 22 of 393 patients with MGUS/biclonal gammopathy of undetermined significance (BGUS) progressed to SMM (6), MM (11), AL (3), or WM (2), and 5 of 16 patients with biclonal SMM progressed to MM. The rate of progression for BGUS was approximately 1% per year, which is similar to MGUS with one monoclonal protein. The median estimated time of progression of biclonal SMM was 2.6 years; similar to monoclonal SMM. For patients with biclonal MM, both M spikes responded to treatment and, upon relapse, the original dominant M protein remained dominant as the disease progressed. In conclusion, the presence of a second monoclonal protein does not appear to affect the progression of precursor states and suggests multiple monoclonal proteins do not clinically impact one another in the course of the disease. Am. J. Hematol. 91:473–475, 2016. © 2016 Wiley Periodicals, Inc.
A Novel Selectable Islet 1 Positive Progenitor Cell Reprogrammed to Expandable and Functional Smooth Muscle Cells
Turner, Elizabeth C., Huang, Chien‐Ling , Sawhney, Neha, Govindarajan, Kalaimathi, Clover, Anthony J. P., Martin, Kenneth, Browne, Tara C., Whelan, Derek , Kumar, Arun , Mackrill, John J. , Wang, Shaohua , Schmeckpeper, Jeffrey , Stocca, Alessia, Pierce, William Gamewell, Leblond, Anne‐Laure , Cai, Liquan , O’Sullivan, Donnchadh , Büneker, Chirlei Klein, Choi, Janet , MacSharry, John , Russell, Stephen J. , Caplice, Noel M. , Ikeda, Yasuhiro , Russell, Stephen J

Mayo Clinic

Stem Cells | February 3, 2016 | Volume: 34 | Issue: 5 | Pages: 1354-1368

10.1002/stem.2319 | PMID 26840832 Get It

AbstractDisorders affecting smooth muscle structure/function may require technologies that can generate large scale, differentiated and contractile smooth muscle cells (SMC) suitable for cell therapy. To date no clonal precursor population that provides large numbers of differentiated SMC in culture has been identified in a rodent. Identification of such cells may also enhance insight into progenitor cell fate decisions and the relationship between smooth muscle precursors and disease states that implicate differentiated SMC. In this study, we used classic clonal expansion techniques to identify novel self-renewing Islet 1 (Isl-1) positive primitive progenitor cells (PPC) within rat bone marrow that exhibited canonical stem cell markers and preferential differentiation towards a smooth muscle-like fate. We subsequently used molecular tagging to select Isl-1 positive clonal populations from expanded and de novo marrow cell populations. We refer to these previously undescribed cells as the PPC given its stem cell marker profile, and robust self-renewal capacity. PPC could be directly converted into induced smooth muscle cells (iSMC) using single transcription factor (Kruppel-like factor 4) knockdown or transactivator (myocardin) overexpression in contrast to three control cells (HEK 293, endothelial cells and mesenchymal stem cells) where such induction was not possible. iSMC exhibited immuno- and cytoskeletal-phenotype, calcium signaling profile and contractile responses similar to bona fide SMC. Passaged iSMC could be expanded to a scale sufficient for large scale tissue replacement. PPC and reprogramed iSMC so derived may offer future opportunities to investigate molecular, structure/function and cell-based replacement therapy approaches to diverse cardiovascular, respiratory, gastrointestinal, and genitourinary diseases that have as their basis smooth muscle cell functional aberrancy or numerical loss.
Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model
Ahmad, Ajaz , Mondal, Sujan Kumar , Banerjee‬‬‬‬‬‬‬‬‬, Rintu , Alkharfy, Khalid M. , Mukhopadhyay, Debabrata , Banerjee, Rajkumar

Mayo Clinic

Molecular Pharmaceutics | February 2, 2016 | Volume: 13 | Issue: 3 | Pages: 1081-1088

10.1021/acs.molpharmaceut.5b00900 | PMID 26832839 Get It

Continuing Medical Education Activity in Echocardiography
Kupsky, Daniel , Newman, Darrell B. , Kumar, Gautam, Maleszewski, Joseph J. , Edwards, William D. , Klarich, Kyle W.

Mayo Clinic

Echocardiography | January 28, 2016 | Volume: 33 | Issue: 2 | Pages: 185-185

10.1111/echo.13195 Get It

LC-MS/MS for Identifying Patients with CYP24A1 Mutations
Ketha, Hemamalini , Kumar, Rajiv , Singh, Ravinder J. , Kumar, Rajiv

Mayo Clinic

Clinical Chemistry | December 30, 2015 | Volume: 62 | Issue: 1 | Pages: 236-242

10.1373/clinchem.2015.244459 | PMID 26585929 Get It

Abstract BACKGROUND Patients have been described with loss-of-function CYP24A1 (cytochrome P450, family 24, subfamily A, polypeptide 1) mutations that cause a high ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D [25(OH)D/24,25(OH)2D], increased serum 1,25-dihydroxyvitamin D, and resulting hypercalcemia, hypercalciuria and nephrolithiasis. A 25(OH)D/24,25(OH)2D ratio that can identify patients who are candidates for confirmatory CYP24A1 genetic testing would be valuable. We validated an LC-MS/MS assay for 24,25(OH)2D (D3 and D2) and determined a 25(OH)D/24,25(OH)2D cutoff to identify candidates for confirmatory genetic testing. METHODS After addition of isotope-labeled internal standard, serum samples were extracted by solid-phase extraction, derivatized with 4-phenyl-1,2,4,-triazoline-3,5-dione, and quantified by LC-MS/MS. We measured 25(OH)D/24,25(OH)2D in 91 healthy patients and 34 patients with clinically suspected CYP24A1-mediated hypercalcemia. RESULTS The limits of detection and quantification were 0.03 (0.2) and 0.1 (0.24) nmol/L, respectively, for 24,25(OH)2D3, and 0.1 (0.23) and 0.5 (1.16) nmol/L for 24,25(OH)2D2. Intra- and interassay imprecision was 4%–15% across the analytical measurement range of 0.1–25 ng/mL (0.2–60 nmol/L). No interference was observed with 25(OH)D and 1,25(OH)2D. 25(OH)D/24,25(OH)2D of 7–35 was observed in healthy patients, whereas in 2 patients with CYP24A1 mutations, 25(OH)D/24,25(OH)2D was significantly increased (99–467; P &lt; 0.001). A 25(OH)D/24,25(OH)2D ratio ≥99 identified patients who were candidates for CYP24A1 genetic testing. CONCLUSIONS Increased 25(OH)D/24,25(OH)2D supports the diagnosis of reduced CYP24A1 activity due to mutations in CYP24A1. Measurement of 25(OH)D/24,25(OH)2D should be considered a part of the clinical workup in patients with hypercalcemia of otherwise unknown etiology.
Serum Parathyroid Hormone Concentrations and Clinical Outcomes in ESRD: A Call for Targeted Clinical Trials
Zand, Ladan , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Seminars in Dialysis | December 17, 2015 | Volume: 29 | Issue: 3 | Pages: 184-188

10.1111/sdi.12457 | PMID 26676210 Get It

AbstractSecondary hyperparathyroidism almost universally accompanies end‐stage renal disease (ESRD). In some, but not all studies, elevated serum parathyroid hormone (PTH) concentrations are associated with increased fracture rates, cardiovascular disease, and mortality in ESRD. The serum concentration of PTH required for optimal bone health and reduced cardiovascular risk in such patients remains elusive. Recent clinical trials have failed to show substantial changes in morbidity and mortality following reductions of elevated serum PTH concentrations. In this review, we will assess some of the difficulties in evaluating elevated serum PTH concentrations, and their association with skeletal fractures and mortality in ESRD patients. We are of the opinion that in the context of ESRD, elevated PTH concentrations occur in conjunction with other comorbid conditions such as diabetes mellitus, malnutrition, hypertension, volume excess, preexisting heart disease, all of which have prevented establishing a precise association between elevated serum PTH concentrations and global or skeletal outcomes. Age, gender, and racial variability among groups make interpretation exceptionally difficult. Analysis of prevalent ESRD populations with secondary hyperparathyroidism should take all these factors into account. We suggest that future clinical trials which examine the usefulness of reductions in serum PTH concentrations be conducted in age, sex, and racially balanced groups, without or with minimal coexisting confounding disease. Furthermore, trials in such populations should have as their primary outcome a reduction in fractures rather than an alteration in mortality.
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
Investigators, The Huntington Study Group PHAROS, Biglan, Kevin , Shoulson, Ira , Kieburtz, Karl , Oakes, David , Kayson, Elise, Shinaman, M. Aileen, Zhao, Hongwei , Romer, Megan, Young, Anne B., Hersch, Steven M. , Penney, Jack, Marder, Karen, Paulsen, Jane S. , Quaid, Kimberly A., Siemers, Eric , Mallonee, William, Suter, Greg, Dubinsky, Richard , Nance, Martha , Bundlie, Scott R., Radtke, Dawn, Kostyk, Sandra K. , Baic, Corrine, Walker, Francis O. , Hunt, Victoria, Chouinard, Sylvain, Wood‐Siverio, Cathy, Corey‐Bloom, Jody , Peavy, Guerry M. , Moskowitz, Carol, Wesson, Melissa, Samii, Ali, Bird, Thomas D. , Lipe, Hillary, Blindauer, Karen, Marshall, Frederick J., Zimmerman, Carol, Goldstein, Jody, Rosas, Diana, Novák, Péter , Caviness, John N., Duffy, Amy, Wheelock, Vicki, Tempkin, Teresa, Seeberger, Lauren , Albin, Roger L. , Racette, Brad A. , Perlman, Susan , Bordelon, Yvette , Martin, W. R. Wayne , Wieler, Marguerite , Raymond, Lynn A. , Decolongon, Joji, Hunter, Christine , Hauser, Robert A. , Furtado, Sarah , Suchowersky, Oksana , Klimek, Mary Lou, Guttman, Mark, Sethna, Rustom, Feigin, Andrew, Cox, Marie, Shannon, Barbara , Percy, Alan K. , Dure, Leon , Harrison, Madaline B. , Higgins, Donald S. , Molho, Eric , Nickerson, Constance, Evans, Sharon, Hobson, Douglas, Singer, Carlos , Gálvez-Jiménez, Néstor, Shannon, Kathleen M. , Comella, Cynthia , Ross, Christopher A. , Hogarth, Penelope , Weiner, William J., Como, Peter G., Kumar, Rajeev , Cotto, Candace, Stout, Julie C. , Brocht, Alicia, Watts, Arthur, Eberly, Shirley , Weaver, Christine , Gusella, James F. , MacDonald, Marcy E., Fahn, Stanley, Shults, Clifford W., Caviness, John, Investigators, The Huntington Study Group PHAROS, Tanner, Caroline M. , Gray, Carolyn Steele , Baic, Corrine L., Caress, James B. , O’Neill, Christine J. , Factor, Stewart Alan , Greenamyre, J. Timothy , Song, David , Adler, Charles H. , Richman, David P. , Chou, Kelvin L. , Perlmutter, Joel S. , Leavitt, Blair R. , Clarke, Lorne A. , Jankovic, Joseph J. , Sanchez‐Ramos, Juan , Johnson, William , Saint‐Hilaire, Marie , Testa, Claudia M. , Rosenblatt, Adam E , Foroud, Tatiana , Myers, Richard H. , Ross, Christopher A , Hauser, Robert A

Mayo Clinic

JAMA Neurology | November 16, 2015 | Volume: 73 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2015.2736 | PMID 26569098 Get It

Penetrating head injuries in children due to BB and pellet guns: a poorly recognized public health risk
Kumar, Ravi , Kumar, Ramesh , Mallory, Grant W., Jacob, Jeffrey T. , Wetjen, Nicholas M. , Foy, Andrew , O’Neill, Brent R., Daniels, David J. , Clarke, Michelle J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 24, 2015 | Volume: 17 | Issue: 2 | Pages: 215-221

10.3171/2015.6.peds15148 | PMID 26496633 Get It

OBJECT Nonpowder guns, defined as spring- or gas-powered BB or pellet guns, can be dangerous weapons that are often marketed to children. In recent decades, advances in compressed-gas technology have led to a significant increase in the power and muzzle velocity of these weapons. The risk of intracranial injury in children due to nonpowder weapons is poorly documented. METHODS A retrospective review was conducted at 3 institutions studying children 16 years or younger who had intracranial injuries secondary to nonpowder guns. RESULTS The authors reviewed 14 cases of intracranial injury in children from 3 institutions. Eleven (79%) of the 14 children were injured by BB guns, while 3 (21%) were injured by pellet guns. In 10 (71%) children, the injury was accidental. There was 1 recognized assault, but there were no suicide attempts; in the remaining 3 patients, the intention was indeterminate. There were no mortalities among the patients in this series. Ten (71%) of the children required operative intervention, and 6 (43%) were left with permanent neurological injuries, including epilepsy, cognitive deficits, hydrocephalus, diplopia, visual field cut, and blindness. CONCLUSIONS Nonpowder guns are weapons with the ability to penetrate a child’s skull and brain. Awareness should be raised among parents, children, and policy makers as to the risk posed by these weapons.